Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Regenerative Medical Technology (RMTG) Equity Ratio (2017 - 2025)

Historic Equity Ratio for Regenerative Medical Technology (RMTG) over the last 9 years, with Q3 2025 value amounting to 6.65.

  • Regenerative Medical Technology's Equity Ratio rose 1965.68% to 6.65 in Q3 2025 from the same period last year, while for Sep 2025 it was 6.65, marking a year-over-year increase of 1965.68%. This contributed to the annual value of 7.16 for FY2024, which is 543.56% up from last year.
  • As of Q3 2025, Regenerative Medical Technology's Equity Ratio stood at 6.65, which was up 1965.68% from 6.47 recorded in Q2 2025.
  • Regenerative Medical Technology's Equity Ratio's 5-year high stood at 0.3 during Q2 2021, with a 5-year trough of 8.47 in Q2 2024.
  • For the 5-year period, Regenerative Medical Technology's Equity Ratio averaged around 4.32, with its median value being 6.47 (2025).
  • As far as peak fluctuations go, Regenerative Medical Technology's Equity Ratio surged by 10016.8% in 2021, and later tumbled by 48171.44% in 2022.
  • Quarter analysis of 5 years shows Regenerative Medical Technology's Equity Ratio stood at 0.73 in 2021, then plummeted by 104.22% to 1.48 in 2022, then crashed by 410.5% to 7.57 in 2023, then increased by 5.44% to 7.16 in 2024, then grew by 7.11% to 6.65 in 2025.
  • Its last three reported values are 6.65 in Q3 2025, 6.47 for Q2 2025, and 7.06 during Q1 2025.